Loading cancer entity…
Loading cancer entity…
Clinical trials
3,386 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04361851 | Study of Dara-Pembro for Multiple Myeloma Patients | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 26, 2022 | clinicaltrials |
| NCT04230031 | Phase II Study of Daratumumab Pre-Mobilization and Post-ASCT in Multiple Myeloma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 21, 2022 | clinicaltrials |
| NCT03964688 |
| Effect of Vitamin C in Autologous Stem Cell Transplantations(VICAST) |
| completed |
| Phase 2 |
| 47 |
| Maastricht University Medical CenterOTHER |
| 1 |
| Apr 20, 2022 |
| clinicaltrials |
| NCT03850522 | PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma | terminated | Phase 2 | 6 | Lene Meldgaard KnudsenOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT03104270 | Combination Study for High Risk Multiple Myeloma Patients | terminated | Phase 2 | 13 | OncotherapeuticsINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05147493 | A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment | unknown | Phase 2 | 51 | Hellenic Society of HematologyOTHER | 1 | Mar 29, 2022 | clinicaltrials |
| NCT05298683 | A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor | unknown | Phase 2 | 108 | Hellenic Society of HematologyOTHER | 1 | Mar 28, 2022 | clinicaltrials |
| NCT01989598 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 40 | Canadian Myeloma Research GroupOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT00792506 | Phase II Clinical Trial of ITF2357 In Patients With Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 1 | ItalfarmacoINDUSTRY | 1 | Feb 2, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT03875495 | A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM) | terminated | Phase 1 / Phase 2 | 9 | Genenta ScienceINDUSTRY | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02424851 | Optimising Renal Outcome in Myeloma Renal Failure(OPTIMAL) | completed | Phase 2 | 31 | Oxford University Hospitals NHS TrustOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04150692 | Escalation of Daratumumab Frequency Following Biochemical Progression in Relapsed/Refractory Multiple Myeloma | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jan 24, 2022 | clinicaltrials |
| NCT04097301 | Study of CAR T-cell Therapy in Acute Myeloid Leukemia and Multiple Myeloma | terminated | Phase 1 / Phase 2 | 8 | AGC Biologics S.p.A.INDUSTRY | 2 | Jan 19, 2022 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT05150522 | B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 9, 2021 | clinicaltrials |
| NCT02086552 | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01793051 | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | completed | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT05066646 | A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)(FUMANBA-1) | unknown | Phase 1 / Phase 2 | 132 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 1 | Nov 23, 2021 | clinicaltrials |
| NCT01421186 | A Phase 1/2a Study of Human Anti-CD 38 Antibody MOR03087 (MOR202) in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 91 | MorphoSys AGINDUSTRY | 2 | Nov 16, 2021 | clinicaltrials |
| NCT00177047 | Autologous Transplant for Multiple Myeloma | completed | Phase 2 / Phase 3 | 363 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 9, 2021 | clinicaltrials |
| NCT05114109 | Isatuximab in Type I Cryoglobulinemia(ICE) | unknown | Phase 2 | 21 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Nov 9, 2021 | clinicaltrials |
| NCT01054144 | Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 13, 2021 | clinicaltrials |
| NCT02951819 | A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma | completed | Phase 2 | 101 | Janssen Scientific Affairs, LLCINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT05055791 | A Study to Evaluate the Safety and Tolerance of SYHX1903 in Patients With Relapsed/Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 312 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Sep 24, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02169791 | Nonmyeloablative Haploidentical Transplant Followed by MLN9708 | completed | Phase 2 | 29 | Northside Hospital, Inc.OTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02045017 | Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency | completed | Phase 2 | 81 | CelgeneINDUSTRY | 8 | Aug 27, 2021 | clinicaltrials |
| NCT03136653 | A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Molecular Partners AGINDUSTRY | 6 | Aug 25, 2021 | clinicaltrials |
| NCT04584307 | Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant(Immuno-POWER) | withdrawn | Phase 2 | 0 | Natalie CallendarOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT00421525 | Phase I/II Study of hLL1 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01101594 | A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 17 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT01720875 | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)(MUKfour) | completed | Phase 2 | 16 | University of LeedsOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT03634800 | Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)(RISE-M) | terminated | Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02265731 | Study Evaluating Venetoclax in Subjects With Hematological Malignancies | completed | Phase 1 / Phase 2 | 38 | AbbVieINDUSTRY | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01946152 | Pomalidomide, Dexamethasone, and Filgrastim-sndz in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT03665155 | First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT00445068 | Efficacy and Safety of LBH589B in Adult Patients With Multiple Myeloma | terminated | Phase 2 | 38 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 14, 2021 | clinicaltrials |
| NCT03567616 | A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | AbbVieINDUSTRY | 3 | Jun 30, 2021 | clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02128230 | UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission | terminated | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT02703779 | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | completed | Phase 2 | 101 | Siddhartha GangulyOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02757326 | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma(ABC-103) | terminated | Phase 1 / Phase 2 | 13 | RedHill Biopharma LimitedINDUSTRY | 1 | Jun 18, 2021 | clinicaltrials |
| NCT03687125 | Tinostamustine Conditioning and Autologous Stem Cell(TITANIUM1) | terminated | Phase 1 / Phase 2 | 6 | Mundipharma-EDO GmbHINDUSTRY | 3 | Jun 18, 2021 | clinicaltrials |
| NCT00967343 | Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor | terminated | Phase 2 / Phase 3 | 40 | Kiadis PharmaINDUSTRY | 7 | Jun 14, 2021 | clinicaltrials |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 11, 2021 | clinicaltrials |
Data updated 24 days agoSource updated Apr 26, 2022source: clinicaltrials